Download PDF
Z Gastroenterol 2002; 40(11): 937-943
DOI: 10.1055/s-2002-35412
Übersicht
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen

Gastrointestinal Side Effects in the Therapy of Rheumatologic DiseasesU. Schiemann1 , H. Kellner1
  • 1Medizinische Poliklinik, Klinikum der Universität München - Innenstadt, Ludwig-Maximilians-Universität München
Further Information

Publication History

Publication Date:
18 November 2002 (online)

Also available at
   Permissions and Reprints
Preview

Zusammenfassung

Die weit verbreitet eingesetzten Antirheumatika können eine Vielzahl gastrointestinaler Komplikationen hervorrufen. Sympto­matische Therapeutika wie Glukokortikoide und nicht-steroidale Antirheumatika sind bekannt für das Auftreten von Magen- und Duodenalulzera, besonders unter ihrer Kombinationsbehandlung. Das Nebenwirkungsspektrum der Basistherapeutika (Methotrexat, Leflunomid, Hydroxy-/Chloroquin, Sulfasalazin) umfasst neben unspezifischen gastrointestinalen Reizsymptomen wie Übelkeit, Erbrechen und Diarrhöen auch die Induktion von ulzerösen Schleimhautläsionen (Methotrexat) und vor allem das Auftreten einer Hepatopathie. Diese kann sich durch eine asymptomatische Erhöhung der Transaminasen oder Cholestaseparameter manifestieren, jedoch in Einzelfällen unter einer Monotherapie (Hydroxy-/Chloroquin, Sulfasalazin), besonders aber unter einer Kombina­tionsbehandlung (Methotrexat + Leflunomid) zur fulminanten Hepatitis führen. Die TNF-α-blockierenden Substanzen (Etanercept, Infliximab) als neue Generation antiinflammatorischer Therapeutika weisen nach derzeitiger klinischer Erfahrung und Datenlage in der Literatur keine relevanten gastrointestinalen Nebenwirkungen auf.

Abstract

Antirheumatic drugs may lead to a number of relevant gastrointestinal complications. Symptomatical treatments with glucocorticoids and non steroidal antirheumatic drugs (NSAD) are known to induce gastric or duodenal ulcers, above all under combination therapies. Side effects of DMARD's (methotrexate, leflunomide, hydroxy/chloroquine, sulfasalazine) include unspecifical gastrointestinal symptoms like nausea, vomiting and diarrhea as well as induction of ulcerative mucosal lesions (methotrexate) and occurrence of a hepatopathy. The latter may appear as an asymptomatical elevation of liver transaminases or cholestase parameters, but can also lead, in some cases of a monothera­py (hydroxy-/chloroqine, sulfasalazine) or combination therapy (methotrexate + leflunomide) to a fulminant hepatitis. TNF-α-inhibiting drugs (etanercept, infliximab) as a new generation of anti-inflammatory therapeutics don't have relevant gastrointestinal side effects according recently published data.

Schlüsselwörter

Rheumatoide Arthitis - Ulcusventriculi - NSAR-Gastropathie

Key words

Rheumatoid arthritis - gastric ulcer - NSAID gastropathy

Literatur

  • 1 Smith M D, Ahern M J, Roberts-Thomson P J. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?.  Ann Rheum Dis. 1988;  47 (1) 28-33
    Search in Google Scholar
  • 2 Hayball P J, Cosh D G, Ahern M J. et al . High dose oral methylprednisolon in patients with rheumatoid arthritis: pharmacokinetics and clinical response.  Eur J Clin Pharmacol. 1992;  42 (1) 85-88
    Search in Google Scholar
  • 3 Saag K G. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence.  Am J Med. 1997;  103 (6A) 31S-39S
    Search in Google Scholar
  • 4 Pearson D, Sheldon P. Effect of corticosteroid on lymphocyte adhe­sion.  Adv Exp Med Biol. 1995;  371A 167-170
    Search in Google Scholar
  • 5 Aglas F, Rainer F, Lipp R W. et al . Effect of steroid treatment on the migration behaviour of neutrophils in patients with early rheumatoid arthritis.  Rheumatol Int. 1997;  17 (4) 137-140
    Search in Google Scholar
  • 6 Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs.  FASEB J. 1987;  1 (2) 89-96
    Search in Google Scholar
  • 7 Saag K G, Koehnke R, Caldwell J R. et al . Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.  Am J Med. 1994;  96 (2) 115-123
    Search in Google Scholar
  • 8 Hernandez-Diaz S, Rodriguez L A. Steroids and risk of upper gastrointestinal complications.  Am J Epidemiol. 2001;  153 (11) 1089-1093
    Search in Google Scholar
  • 9 Conn H O, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.  J Intern Med. 1994;  236 619-632
    Search in Google Scholar
  • 10 Piper J M, Ray W A, Daugherty J R. et al . Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.  Ann Intern Med. 1991;  114 735-740
    Search in Google Scholar
  • 11 Garcia R odriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.  Arthritis Res. 2001;  3 (2) 98-101
    Search in Google Scholar
  • 12 Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ­ARAMIS database.  Am J Ther. 2000;  7 (2) 115-121
    Search in Google Scholar
  • 13 Ceuppens J L, Rodriguez M A, Goodwin J S. Non-steroidal anti-inflammatory agent inhibit the synthesis if IgM rheumatoid factor in vitro.  Lancet. 1982;  1 (8271) 528-530
    Search in Google Scholar
  • 14 Goodwin J S. Mechanism of action of nonsteroidal anti-inflammatory agents.  Am J Med. 1984;  77 (1A) 57-64
    Search in Google Scholar
  • 15 Daymond T J, Rowell F J. Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumaoid arthritis following tiaprofenic acid or indomethacin treatment.  Drugs. 1988;  35 (Suppl. 1) 4-8
    Search in Google Scholar
  • 16 Raskin J B. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy.  Am J Med. 1999;  106 (5B) 3S-12S
    Search in Google Scholar
  • 17 Fries J F, Williams C A, Bloch D A. et al . Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.  Am J Med. 1991;  91 (3) 213-222
    Search in Google Scholar
  • 18 Stehen K S, Lems W F, Aersen J. et al . Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis.  Ann Rheum Dis. 2001;  60 (5) 443-447
    Search in Google Scholar
  • 19 Lanas A, Serrano P, Bajador E. et al . Evidence of aspirin use in both upper and lower gastrointestinal perforation.  Gastroenterology. 1997;  112 683-689
    Search in Google Scholar
  • 20 Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.  N Engl J Med. 1999;  24 1888-1899
    Search in Google Scholar
  • 21 Cheatum D E, Arvanitakis C, Gumpel M. et al . An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs.  Clin Ther. 1999;  21 (6) 992-1003
    Search in Google Scholar
  • 22 Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications.  J Rheumatol. 1999;  26 (Suppl. 26) 18-24
    Search in Google Scholar
  • 23 Schwake L, Schenker T, Schwake S. et al . Ulcers of the colon in association with nonsteroidal anti-inflammatory drugs (NSAID) - a rare cause of gastrointestinal bleeding? Report of 3 cases.  Z Gastroenterol. 2000;  38 (12) 957-961
    Search in Google Scholar
  • 24 Lugea A, Antolin M, Mourelle M. et al . Deranged hydrophobic barrier of the gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs.  Gastroenterology. 1997;  112 1931-1939
    Search in Google Scholar
  • 25 Seitz S, Boelsterli U A. Diclofenac acyl glucuronide, a major biliary ­metabolite, is directly involved in small intestinal injury in ras.  ­Gastroenterology. 1998;  115 1476-1482
    Search in Google Scholar
  • 26 Gut A, Halter F, Ruchti C. Nichtsteroidale Antirheumatika und Azetylsalizylsäure: Nebenwirkungen distal des Duodenums.  Schw Med Wochenschr. 1996;  126 616-623
    Search in Google Scholar
  • 27 Bridges A J, Marshall J B, Diaz-Arias A A. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy.  Am J Med. 1990;  89 526-527
    Search in Google Scholar
  • 28 Willett L R, Carson J L, Strom B L. Epidemiology of gastrointestinal damage associated with non-steroidal anti-inflammatory drugs.  Drug Safety. 1994;  10 170-181
    Search in Google Scholar
  • 29 Gentric A, Pennec Y L. Diclofenac-induced pseudomembranous colitis.  Lancet. 1992;  340 126-127
    Search in Google Scholar
  • 30 Israel L H, Koea J B, Stewar I D. et al . Nonsteroidal anti-inflammatory drug-induced strictures of the colon: report of a case and review of the literature.  Dis Colon Rectum. 2001;  44 (9) 1362-1364
    Search in Google Scholar
  • 31 Rooney T W, Furst D E, Koehnke R. et al . Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate.  J Rheumatol. 1993;  20 (8) 1297-1302
    Search in Google Scholar
  • 32 Koch M, Dezi A, Tarquini M. et al . Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications.  Dig Liver Dis. 2000;  32 (2) 138-151
    Search in Google Scholar
  • 33 Bianchi P orro G, Lazzaroni M, Imbesi V. et al . Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.  Dig Liver Dis. 2000;  32 (3) 201-208
    Search in Google Scholar
  • 34 Goldstein J L. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis?.  Eur J Gastroenterol Hepatol. 2000;  12 (Suppl. 1) S11-15
    Search in Google Scholar
  • 35 Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.  Curr Med Chem. 2000;  7 (11) 1121-1129
    Search in Google Scholar
  • 36 Benson W G, Zhao S Z, Burke T A. et al . Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.  J Rheumatol. 2000;  27 (8) 1876-1883
    Search in Google Scholar
  • 37 Silverstein F E, Faich G, Goldstein J L. et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.  JAMA. 2000;  284 (10) 1247-1255
    Search in Google Scholar
  • 38 Bombardier C, Laine L, Reicin A. et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 (21) 1520-1528
    Search in Google Scholar
  • 39 Goldstein J L, Correa P, Zhao W W. et al . Reduced incidence of gastro­duodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.  Am J Gastroenterol. 2001;  96 (4) 1019-1027
    Search in Google Scholar
  • 40 Hawkey C J, Tulassay Z, Szczepanski L. et al . Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.  Lancet. 1998;  352 1016-1021
    Search in Google Scholar
  • 41 Chan F KL, Sung J JY, Chun S CS. et al . Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.  Lancet. 1997;  350 975-979
    Search in Google Scholar
  • 42 Hawkey C J. What consideration should be given to Helicobacter ­pylori in treating nonsteroidal anti-inflammatory drug ulcers?.  Eur J Gastroenterol Hepatol. 2000;  12 (Suppl. 1) 17-20
    Search in Google Scholar
  • 43 Chan F KL, To K F, Wu J CY. et al . Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs.  Lancet. 2002;  359 9-13
    Search in Google Scholar
  • 44 Huang J O, Sridhar S, Hunt R H. Role of Helicobacer pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.  Lancet. 2002;  359 14-22
    Search in Google Scholar
  • 45 Thompson R N, Watts C, Edelman J. et al . A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis.  J Rheumatol. 1984;  11 760-763
    Search in Google Scholar
  • 46 Andersen P A, West S G, OŽDell J R. et al . Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.  Ann Intern Med. 1985;  103 489-496
    Search in Google Scholar
  • 47 Weinblatt M E, Coblyn J S, Fox D A. et al . Efficacy of low-dose methotrexate in rheumatoid arthritis.  N Engl J Med. 1985;  312 818-822
    Search in Google Scholar
  • 48 Williams H J, Willkens R F, Samuelson C OJ. et al . Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.  Arthritis Rheum. 1985;  28 721-730
    Search in Google Scholar
  • 49 Budzik G P, Colletti L M, Faltynek C R. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.  Life Sci. 2000;  66 2297-2307
    Search in Google Scholar
  • 50 Hornung N, Stenfaard-Pedersen K, Ehrnrooth E. et al . The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells.  Clin Exp Rheumatol. 2000;  18 691-698
    Search in Google Scholar
  • 51 Wiewiorowski M, Graczyk J. The effective of methotrexate on immune response cells in rheumatoid arthritis.  Acta Pol Pharm. 2000;  57 (Suppl.) 138-139
    Search in Google Scholar
  • 52 Mello S B, Barros D M, Silva A S. et al . Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.  Rheumatology. 2000;  39 533-536
    Search in Google Scholar
  • 53 Seitz M, Zwicker M, Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment.  J Rheumatol. 2001;  28 496-501
    Search in Google Scholar
  • 54 Cutolo M, Bisso A, Sulli A. et al . Antiproliferative and antiinflmammatory effects of methotrexae on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis.  J Rheumatol. 2000;  27 2551-2557
    Search in Google Scholar
  • 55 Wluka A, Buchbinder R, Mylvaganam A. et al . Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.  J Rheumatol. 2000;  27 1864-1871
    Search in Google Scholar
  • 56 Baehr P H, McDonald G B. Esophageal disorders caused by infection, systemic illness, medications, radiation, and trauma. Feldman M, Scharschmidt BF, Sleisenger MH Gastrointestinal and liver disease. Pathophysiology, diagnosis, management Philadelphia; Saunders 1998: 519-539
    Search in Google Scholar
  • 57 Sampaio-Barros P D, Costallat L, Berolo M B. et al . Methotrexate in the treatment of ankylosing spondylitis.  Scand J Rheumatol. 2000;  29 160-162
    Search in Google Scholar
  • 58 Hirshberg B, Muszkat M, Schlesinger O. et al . Safety of low dose methotrexate in elderly patients with rheumatoid arthritis.  Postgrad Med J. 2000;  76 787-789
    Search in Google Scholar
  • 59 Ito S, Nakazono K, Murasawa A. et al . Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.  Arthritis Rheum. 2001;  44 339-342
    Search in Google Scholar
  • 60 Scapa E, Yona E, Amram L. Cecal ulceration due to methotrexate.  Isr Med Assoc J. 2001;  3 230
    Search in Google Scholar
  • 61 Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy.  J Rheumatol. 2001;  28 251-256
    Search in Google Scholar
  • 62 Landewe R B, van den Borne B E, Breedveld F C. et al . Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.  Lancet. 2000;  355 1616-1617
    Search in Google Scholar
  • 63 Bressolle F, Kinowski J M, Morel J. et al . Folic acid alters methotrexate availability in patients with rheumatoid arthritis.  J Rheumatol. 2000;  27 2110-2114
    Search in Google Scholar
  • 64 Shahin A A, Ismail M M, Saleh A M. et al . Protective effect of folinic acid on low-dose methotrexate genotoxicity.  Z Rheumatol. 2001;  60 63-68
    Search in Google Scholar
  • 65 Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide InvestigatorsŽ Group.  J Rheumatol Suppl. 1998;  53 27-32
    Search in Google Scholar
  • 66 Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.  Expert Opin Pharmacother. 2001;  2 125-137
    Search in Google Scholar
  • 67 Fox R I, Herrmann M L, Frangou C G. et al . Mechanism of action for leflunomide in rheumatoid arthritis.  Clin Immunol. 1999;  93 198-208
    Search in Google Scholar
  • 68 Strand V, Tugwell P, Bombardier C. et al . Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexat or placebo in patients with active rheumatoid arthritis.  Arthritis Rheum. 1999;  42 1870-1878
    Search in Google Scholar
  • 69 Strand V, Cohen S, Schiff M. et al . Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methorexat.  Arch Intern Med. 1999;  159 2542-2550
    Search in Google Scholar
  • 70 Smolen J S, Kalden J R, Scott D L. et al . Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.  Lancet. 1999;  353 259-266
    Search in Google Scholar
  • 71 Hewitson P J, Debroe S, McBride A. et al . Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications.  J Clin Pharm Ther. 2000;  25 295-302
    Search in Google Scholar
  • 72 Kraan M C, Reece R J, Barg E C. et al . Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.  Arthritis Rheum. 2000;  43 1820-1830
    Search in Google Scholar
  • 73 Kraan M C, de Koster B M, Elfereink J G. et al . Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexat in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.  Arthritis Rheum. 2000;  43 1488-1495
    Search in Google Scholar
  • 74 Emery P, Breedveld F C, Lemmel E M. et al . A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.  Rheumatology. 2000;  39 655-665
    Search in Google Scholar
  • 75 Schattenkirchner M. The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.  Immunopharmacology. 2000;  47 291-298
    Search in Google Scholar
  • 76 Coblyn J S, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis.  Arthritis Rheum. 2001;  44 1048-1051
    Search in Google Scholar
  • 77 Goldenberg M M. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.  Clin Ther. 1999;  21 1837-1852
    Search in Google Scholar
  • 78 Kremer J R, Caldwell J R, Cannon G W. et al . Combination of lefkunomide and methotrexate in patients with rheumatoid arthritis.  Arthritis Rheum. 2000;  43 (Suppl. 9) 224: A948
    Search in Google Scholar
  • 79 Reinhold-Keller E, Gross W L. Leflunomid zur Behandlung der rheumatoiden Arthritis.  Dt Aerzteblatt. 2001;  98 A 1881-1887
    Search in Google Scholar
  • 80 Husain Z, Runge L A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole.  J Rheumatol. 1980;  7 (6) 825-830
    Search in Google Scholar
  • 81 Haar D, Solvkjaer M, Unger B. et al . A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.  Scand J Rheumatol. 1993;  22 (3) 113-118
    Search in Google Scholar
  • 82 Furst D E, Lindsley H, Baehge B. et al . Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.  Arthritis Rheum. 1999;  42 (2) 357-365
    Search in Google Scholar
  • 83 Durieux S, Rozenberg S, Bourgeois P. Complications of colonic diverticular disease during rheumatoid poylarthritis: 7 cases.  Rev Med Interne. 1999;  20 (1) 50-53
    Search in Google Scholar
  • 84 Kim W U, Seo Y I, Park S H. et al . Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis.  Ann Rheum Dis. 2001;  60 (5) 514-517
    Search in Google Scholar
  • 85 van Riel P L, van Gestel A M, van de Putte L B. Long-term usage and ­side-effect profile of sulphasalazine in rheumatoid arthritis.  Br J Rheumatol. 1995;  34 (Suppl. 2) 40-42
    Search in Google Scholar
  • 86 Rodenburg R J, Ganga A, van Lent P L. et al . The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis.  Arthritis Rheum. 2000;  43 (9) 1941-1950
    Search in Google Scholar
  • 87 Hayllar J, Smith T, Macpherson A. et al . Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazin and other disease-modifying antirheumatic drugs.  Arthritis Rheum. 1994;  37 (8) 1146-1150
    Search in Google Scholar
  • 88 Clohen D O, Reda D J, Weisman M H. et al . Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis.  Arthritis Rheum. 1996;  39 (12) 2004-2012
    Search in Google Scholar
  • 89 Rojkovich B, Hodinka L, Balint G. et al . Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis.  Scand J Rheumatol. 1999;  28 (4) 216-221
    Search in Google Scholar
  • 90 Mundo A, Pedone V, Lamanna G. et al . Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis.  Clin Ter. 1997;  148 (1-2) 7-13
    Search in Google Scholar
  • 91 Jung J H, Jun J B, Yoo D H. et al . High toxicity of sulfasalazine in adult-onset Still's disease.  Clin Exp Rheumatol. 2000;  18 (2) 245-248
    Search in Google Scholar
  • 92 Weinblatt M E, Kremer J M, Bankhurst A D. et al . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.  N Engl J Med. 1999;  28: 340 (4) 253-259
    Search in Google Scholar
  • 93 Moreland L W, Schiff M H, Baumgartner S W. et al . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.  Ann Intern Med. 1999;  130 (6) 478-486
    Search in Google Scholar
  • 94 Hamilton K, Clair E W. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.  Expert Opin Pharmacother. 2000;  1 (5) 1041-1052
    Search in Google Scholar
  • 95 Bathon J M, Martin R W, Fleischmann R M. et al . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.  N Engl J Med. 2000;  343 (22) 1586-1593
    Search in Google Scholar
  • 96 Lipsky P E, van der Heijde D M, St C lair EW. et al . Infliximab and methotrexate in the treatment of rheumatoid arthritis.  N Engl J Med. 2000;  343 (22) 1594-1602
    Search in Google Scholar
  • 97 Ulfgren A K, Andersson U, Engstrom M. et al . Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.  Arthritis Rheum. 2000;  43 (11) 2391-2396
    Search in Google Scholar
  • 98 Schaible T F. Long term safety of infliximab.  Can J Gastroenterol. 2000;  14 (Suppl. C) 29C-32C
    Search in Google Scholar
  • 99 Baghai M, Osmon D R, Wolk D M. et al . Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.  Mayo Clin Proc. 2001;  76 (6) 653-656
    Search in Google Scholar
  • 100 Charles P J, Smeenk R J, De Jong J. et al . Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in a open-label and randomized placebo-controlled trials.  Arthritis Rheum. 2000;  43 (11) 2383-2390
    Search in Google Scholar
  • 101 Russell E, Zeihen M, Wergin S. et al . Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays.  Arthritis Rheum. 2000;  43 (4) 944
    Search in Google Scholar
  • 102 Bloom B J. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis.  Arthritis Rheum. 2000;  43 (11) 2606-2608
    Search in Google Scholar
  • 103 Allanore Y, Bremont C, Kahan A. et al . Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept.  Clin Exp Rheumatol. 2001;  19 (3) 356-357
    Search in Google Scholar
  • 104 Sandborn W J, Hanauer S B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.  Inflamm Bowel Dis. 1999;  5 (2) 119-133
    Search in Google Scholar
  • 105 Maini R, St C lair EW, Breedveld F. et al . Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate.  Lancet. 1999;  354 1932-1939
    Search in Google Scholar
  • 106 Kavanaugh A, Keenan G, DeWoody K. et al . Long-term follow-up of patients treated with infliximab in clinical trial.  Arthritis Rheum. 2001;  44 (9) Suppl. Abstract No. 173
    Search in Google Scholar
  • 107 Gridley G, McLaughlin J K, Ekbom A. et al . Incidence of cancer among patients with rheumatoid arthritis.  J Natl Cancer Inst. 1993;  85 (4) 307-311
    Search in Google Scholar
  • 108 Baecklund E, Ekbom A, Sparen P. et al . Disease activity and risk of lymphoma in patients with rheumatoid arthritis.  BMJ. 1998;  317 180-181
    Search in Google Scholar
  • 109 Moreland L W, Cohen S B, Baumgartner S W. et al . Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.  J Rheumatol. 2001;  28 (6) 1238-1244
    Search in Google Scholar
  • 110 Feldmann M, Maini R N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?.  Annu Rev Immunol. 2001;  19 163-196
    Search in Google Scholar

Dr. med. Uwe Schiemann

Medizinische Poliklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München

Pettenkoferstraße 8a

80336 München

Email: uwe.schiemann@pk-i.med.uni-muenchen.de